Status:
COMPLETED
ACT MALI: Treatment of Malaria Based on Combination Therapies
Lead Sponsor:
Sanofi
Conditions:
Malaria
Eligibility:
All Genders
6+ years
Phase:
PHASE4
Brief Summary
Test the hypothesis that repeated administration of Artesunate/Amiodaquine, Artesunate/Sulfadoxine-Pyrimethamine and Arthemeter-Lufemantrine for the treatment of consecutive episodes of uncomplicated ...
Eligibility Criteria
Inclusion
- Body weight \> 5kg
- Residence in the investigator site area for the duration of the trial
- Axillary temperature ≥ 37,5°C at Day 0
- Confirmed Plasmodium falciparum infection,with parasitemia range from 2000 to 200000 asexual parasites /µl of blood
Exclusion
- Danger signs or signs of severe malaria
- Other severe illnesses
- Allergy to one of the drugs
- Pregnant women
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
780 Patients enrolled
Trial Details
Trial ID
NCT00452907
Start Date
July 1 2005
End Date
June 1 2007
Last Update
February 17 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis Administrative Office
Bougoula, Mali